Showing 5021-5030 of 5646 results for "".
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- Ribomic Enters License Agreement with AJU Pharma for RBM-007 in AMDhttps://modernod.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-amd/2477400/Ribomic announced that it has signed a license agreement with Korean pharmaceutical company AJU Pharm Co. for RBM-007 for the indication of the exudative age-related macular degeneration (AMD) in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Mala
- AAO Provides Updated COVID-19 Guidance for Outpatient Clinics and Elective Surgeryhttps://modernod.com/news/aao-provides-updated-guidance-for-outpatient-clinics-and-elective-surgery/2477395/In response to the state of national emergency declared at the federal level, particularly as COVID-19 progresses in a given community, ophthalmologists should seriously consider both the intensity of clinic scheduling and the issue of elective surgeries, particularly in elderly patients and thos
- The Outpatient Ophthalmic Surgery Society (OOSS) Releases Statement Regarding COVID-19 Outbreakhttps://modernod.com/news/ooss-releases-statement-regarding-covid-19-outbreak/2477392/The Outpatient Ophthalmic Surgery Society (OOSS) has released a statement to its membership providing information and resources on how to establish ASC procedures if your community is directly affected by the COVID-19 outbreak. The statement reads: Dear Colleagues, In the cu
- CooperVision Seeks Proposals for Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-science-and-technology-awards/2477387/CooperVision is now accepting submissions for its
- CDC Updates Guidance for Public Gatheringshttps://modernod.com/news/cdc-updates-guidance-for-coronavirus-disease-2019/2477385/On Sunday, the Centers for Disease Control and Prevention (CDC) updated its guidance regarding public gatherings during the COVID-19 outbreak. The CDC now recommends that for the next 8 weeks, organizers (whether groups or individuals) cancel or postpone in-person events that consist of 50
- The Vision Council Examines Consumers’ Attitudes About COVID-19 in a Survey for Its Membershttps://modernod.com/news/the-vision-council-examines-consumers-attitudes-about-covid-19-in-a-survey-for-its-members/2477382/The Vision Council released a new COVID-19 Optical Impact consumer survey. Conducted by The Vision Council’s research team in February, the study surveyed more than 10,000 adults across the U.S. and was designed to measure respondents’ level of concern over exposure to COVID-19, including measure
- Top Contact Lens Experts Dispel Misinformation Regarding Coronavirushttps://modernod.com/news/top-contact-lens-experts-dispel-misinformation-regarding-coronavirus/2477381/Three of the world’s most published researchers in eye health are responding to misinformation circulating regarding contact lens and spectacles/glasses wear amidst Novel Coronavirus/COVID-19 pandemic. Lyndon Jones, director of the Centre for Ocular Research & Education (CORE) at the U
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- Alcon Announces European Launch of Vivity Presbyopia-Correcting IOL With X-WAVE Technologyhttps://modernod.com/news/alcon-announces-european-launch-of-vivity-presbyopia-correcting-iol-with-x-wave-technology/2477377/Alcon announced that the AcrySof IQ Vivity IOL is now commercially available in select European markets, with additional countries to follow throughout 2020. The latest innovation in Alcon’s portfolio of presbyopia-correcting IOLs (PC-IOLs), Vivity is the first-of-its-kind, extended range